MARKSANS Q4 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹856 Cr
verified against source
Revenue YoY
12.5%
reported change
EBITDA
₹601 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Marksans Pharma delivered a standout Q4 FY26 with Rs 856 crore revenue (+20.8% YoY) and 22.8% EBITDA margin, demonstrating strong operating leverage. Full-year FY26 revenue crossed Rs 3,000 crore for the first time at Rs 2,951 crore, with PAT of Rs 420 crore and EBITDA margin expanding to 20.4%. North America remains the growth engine at Rs 1,533 crore (+24% YoY), contributing 52% of consolidated revenue, while UK/EU delivered its highest-ever quarterly revenue. Australia surged 61.3% YoY with entry into prescription generics via Nova Pharma. Management targets Rs 4,000 crore revenue in two years with 15-20% growth for FY27. Raw material inflation (20-30% on petroleum-linked inputs) poses a near-term Q1 FY27 headwind, though the company holds 5-6 months of inventory and has forex cover. Cash position of Rs 990 crore provides M&A flexibility, with two targets under active due diligence. Key risks include raw material cost escalation, customer contract renegotiation dynamics, and competitive US pricing pressure.
Colored figures show movement against the previous available record.
Guidance to track
- Management confirmed the Rs 4,000 crore revenue target remains on track within the next two years, underpinned by new market entries and pipeline expansion.
- Conservatively guiding for 15-20% revenue growth in FY27, citing confidence in execution and multiple growth drivers across geographies.
- Despite raw material inflation headwinds in Q1 FY27, management expects full-year FY27 EBITDA margins to remain in the 20-21% range.
- With Rs 990 crore cash on books, management is in active due diligence on one target and preliminary discussions on another, expecting transactions to close in 2027.
Risks flagged
- Petroleum-linked raw materials seeing 20-30% price escalation due to geopolitical tensions. While 5-6 months of inventory provides near-term cushion, Q1 FY27 margins may face pressure if conflict persists.
- Long-term OTC contracts (typically 2-year fixed) create inflexibility; invoking force majeure triggers renegotiation, which customers are reluctant to accept given expectations of imminent conflict resolution.
- Management acknowledged US market is highly competitive with significant pricing pressure, potentially constraining margin expansion despite strong volume growth trajectory.
- Analyst questioned why company hasn't increased stake in Australian entity (currently 60% owned) given strong performance and Rs 1,000 crore cash position; management deflected without clear rationale.
Key quotes
- We crossed 3,000 crores in net income for the first time and delivered our highest ever profitability. More importantly, we strengthen the quality of business through geographical diversification, portfolio expansion, improved margins and strong cash generation.
- EBITDA for the period was rupees 601 crores with the EBITDA margin at 20.4%. Profit after tax was at rupees 420 crores. EPS for FY26 was rupees 9.22.
- We are witnessing raw materials which directly or indirectly have petroleum related ingredients involved in that. So we are seeing a price escalation of 20 to 30% on these raw materials.
Research modules